254 related articles for article (PubMed ID: 30837874)
1. Influence of CYP2C19 Metabolizer Status on Escitalopram/Citalopram Tolerability and Response in Youth With Anxiety and Depressive Disorders.
Aldrich SL; Poweleit EA; Prows CA; Martin LJ; Strawn JR; Ramsey LB
Front Pharmacol; 2019; 10():99. PubMed ID: 30837874
[TBL] [Abstract][Full Text] [Related]
2. CYP2C19-Guided Escitalopram and Sertraline Dosing in Pediatric Patients: A Pharmacokinetic Modeling Study.
Strawn JR; Poweleit EA; Ramsey LB
J Child Adolesc Psychopharmacol; 2019 Jun; 29(5):340-347. PubMed ID: 30817183
[No Abstract] [Full Text] [Related]
3. Escitalopram pharmacogenetics: CYP2C19 relationships with dosing and clinical outcomes in autism spectrum disorder.
Bishop JR; Najjar F; Rubin LH; Guter SJ; Owley T; Mosconi MW; Jacob S; Cook EH
Pharmacogenet Genomics; 2015 Nov; 25(11):548-54. PubMed ID: 26313485
[TBL] [Abstract][Full Text] [Related]
4. Association between CYP metabolizer phenotypes and selective serotonin reuptake inhibitors induced weight gain: a retrospective cohort study.
Ricardo-Silgado ML; Singh S; Cifuentes L; Decker PA; Gonzalez-Izundegui D; Moyer AM; Hurtado MD; Camilleri M; Bielinski SJ; Acosta A
BMC Med; 2022 Jul; 20(1):261. PubMed ID: 35879764
[TBL] [Abstract][Full Text] [Related]
5. Effect of CYP2C19 Pharmacogenetic Testing on Predicting Citalopram and Escitalopram Tolerability and Efficacy: A Retrospective, Longitudinal Cohort Study.
Mahajna M; Abu Fanne R; Berkovitch M; Tannous E; Vinker S; Green I; Matok I
Biomedicines; 2023 Dec; 11(12):. PubMed ID: 38137466
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetics to Predict Adverse Events Associated With Antidepressants.
Rossow KM; Aka IT; Maxwell-Horn AC; Roden DM; Van Driest SL
Pediatrics; 2020 Dec; 146(6):. PubMed ID: 33234666
[TBL] [Abstract][Full Text] [Related]
7. Impact of cytochrome P450 2C19 polymorphisms on citalopram/escitalopram exposure: a systematic review and meta-analysis.
Chang M; Tybring G; Dahl ML; Lindh JD
Clin Pharmacokinet; 2014 Sep; 53(9):801-11. PubMed ID: 25154506
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetic Factors Influence Escitalopram Pharmacokinetics and Adverse Events in Youth with a Family History of Bipolar Disorder: A Preliminary Study.
Honeycutt DC; Blom TJ; Ramsey LB; Strawn JR; Bruns KM; Welge JA; Patino LR; Singh MK; DelBello MP
J Child Adolesc Psychopharmacol; 2024 Feb; 34(1):42-51. PubMed ID: 38377518
[No Abstract] [Full Text] [Related]
9. Influence of
Islam F; Magarbeh L; Elsheikh SSM; Kloiber S; Espinola CW; Bhat V; Frey BN; Milev R; Soares CN; Parikh SV; Placenza F; Hassel S; Taylor VH; Leri F; Blier P; Uher R; Farzan F; Lam RW; Turecki G; Foster JA; Rotzinger S; Kennedy SH; Müller DJ
Can J Psychiatry; 2024 Mar; 69(3):183-195. PubMed ID: 37796764
[TBL] [Abstract][Full Text] [Related]
10. Escitalopram : a review of its use in the management of major depressive and anxiety disorders.
Waugh J; Goa KL
CNS Drugs; 2003; 17(5):343-62. PubMed ID: 12665392
[TBL] [Abstract][Full Text] [Related]
11. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIs.
Brouwer JMJL; Nijenhuis M; Soree B; Guchelaar HJ; Swen JJ; van Schaik RHN; Weide JV; Rongen GAPJM; Buunk AM; de Boer-Veger NJ; Houwink EJF; van Westrhenen R; Wilffert B; Deneer VHM; Mulder H
Eur J Hum Genet; 2022 Oct; 30(10):1114-1120. PubMed ID: 34782755
[TBL] [Abstract][Full Text] [Related]
12. Escitalopram and Sertraline Population Pharmacokinetic Analysis in Pediatric Patients.
Poweleit EA; Taylor ZL; Mizuno T; Vaughn SE; Desta Z; Strawn JR; Ramsey LB
Clin Pharmacokinet; 2023 Nov; 62(11):1621-1637. PubMed ID: 37755681
[TBL] [Abstract][Full Text] [Related]
13. The Effects of CYP2C19 Genotype on Proxies of SSRI Antidepressant Response in the UK Biobank.
Wong WLE; Fabbri C; Laplace B; Li D; van Westrhenen R; Lewis CM; Dawe GS; Young AH
Pharmaceuticals (Basel); 2023 Sep; 16(9):. PubMed ID: 37765085
[TBL] [Abstract][Full Text] [Related]
14. CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP.
Huezo-Diaz P; Perroud N; Spencer EP; Smith R; Sim S; Virding S; Uher R; Gunasinghe C; Gray J; Campbell D; Hauser J; Maier W; Marusic A; Rietschel M; Perez J; Giovannini C; Mors O; Mendlewicz J; McGuffin P; Farmer AE; Ingelman-Sundberg M; Craig IW; Aitchison KJ
J Psychopharmacol; 2012 Mar; 26(3):398-407. PubMed ID: 21926427
[TBL] [Abstract][Full Text] [Related]
15. Effects of Cytochrome P450 2C19 Genetic Polymorphisms on Responses to Escitalopram and Levels of Brain-Derived Neurotrophic Factor in Patients With Panic Disorder.
He Q; Mei Y; Liu Y; Yuan Z; Zhang J; Yan H; Shen L; Zhang Y
J Clin Psychopharmacol; 2019; 39(2):117-123. PubMed ID: 30742590
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetically Guided Escitalopram Treatment for Pediatric Anxiety Disorders: Protocol for a Double-Blind Randomized Trial.
Strawn JR; Poweleit EA; Mills JA; Schroeder HK; Neptune ZA; Specht AM; Farrow JE; Zhang X; Martin LJ; Ramsey LB
J Pers Med; 2021 Nov; 11(11):. PubMed ID: 34834540
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy and tolerability of escitalopram in anxiety disorders: a review].
Pelissolo A
Encephale; 2008 Sep; 34(4):400-8. PubMed ID: 18922243
[TBL] [Abstract][Full Text] [Related]
18. CYP2C19 variation, not citalopram dose nor serum level, is associated with QTc prolongation.
Kumar Y; Kung S; Shinozaki G
J Psychopharmacol; 2014 Dec; 28(12):1143-8. PubMed ID: 25122046
[TBL] [Abstract][Full Text] [Related]
19. [Mechanisms of action of antidepressants: new data from Escitalopram].
Fabre V; Hamon M
Encephale; 2003; 29(3 Pt 1):259-65. PubMed ID: 12876551
[TBL] [Abstract][Full Text] [Related]
20. Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials.
Gorman JM; Korotzer A; Su G
CNS Spectr; 2002 Apr; 7(4 Suppl 1):40-4. PubMed ID: 15131492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
